SCHEMBL5459265

SCHEMBL5459265

Cc1nc(NC(=O)Nc2ccc(N3CCNCC3)nc2)sc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
AURKA O14965 1/20 0.44
KDR P35968 1/20 0.44
FLT3 P36888 1/20 0.44
DGAT1 O75907 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPT P10636 3/20 0.42
KDM4E B2RXH2 2/20 0.42
KCNH2 Q12809 1/20 0.42
CACNA1C Q13936 1/20 0.42
ASIC3 Q9UHC3 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 1/20 0.42
MAPK7 Q13164 1/20 0.42
SLC27A1 Q6PCB7 1/20 0.41
CLK2 P49760 3/20 0.41
DYRK1A Q13627 3/20 0.41
CLK3 P49761 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466077 0.86 RAB9A (0.52) RAB9APOLBSMN1; SMN2DGAT1L3MBTL1
SCHEMBL5465623 0.84 RAB9A (0.60) RAB9APOLBSMN1; SMN2AURKAKDR
SCHEMBL5452148 0.81 WNT3A (0.52) RAB9APOLBSMN1; SMN2DGAT1MAPT
SCHEMBL5460908 0.78 RAB9A (0.55) RAB9APOLBSMN1; SMN2FLT3L3MBTL1
SCHEMBL5459843 0.73 RAB9A (0.55) RAB9ASMN1; SMN2L3MBTL1MAPTKDM4E
SCHEMBL5451242 0.73 NPC1 (0.53) RAB9APOLBSMN1; SMN2DGAT1MAPT
SCHEMBL7490372 0.72 MAPT (0.59) RAB9AL3MBTL1MAPTKDM4ECYP1A2
SCHEMBL5452137 0.72 MEN1 (0.55) RAB9APOLBSMN1; SMN2MAPTKDM4E
SCHEMBL5466937 0.72 KMT2A (0.60) RAB9APOLBSMN1; SMN2MAPTKDM4E
SCHEMBL5466996 0.72 DGAT1 (0.55) RAB9ASMN1; SMN2DGAT1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 RAB9A 1528/4885POLB 4280/4885SMN1; SMN2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.